Bruce M. Psaty, MD, PhD, is a general internist and cardiovascular disease epidemiologist with interests and expertise in pharmaco-epidemiology, pharmacogenetics, genomics, and drug safety. Also a professor of medicine, epidemiology, and health services at the University of Washington (UW), he co-directs the UW’s Cardiovascular Health Research Unit.
Dr. Psaty’s work includes population-based case-control studies of myocardial infarction, stroke, atrial fibrillation, and venous thromboembolism conducted at Kaiser Permanente Washington. His primary research interests include:
His several current National Institutes of Health-funded projects involve largescale collaborative discovery efforts and use genetics to understand the human biology of cardiovascular diseases and risk factors. He is a founding member of the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (CHARGE), which conducts genome-wide association studies in collaborating cohorts, including the Cardiovascular Health Study and the Multi-Ethnic Study of Atherosclerosis, funded by the National Heart, Lung, and Blood Institute (NHLBI). He also teaches and mentors students, fellows, and junior faculty in medicine and epidemiology.
A national leader in encouraging better postmarket surveillance of approved medications, Dr. Psaty was a member of the U.S. Food and Drug Administration (FDA)’s Science Board (2011-2018), a committee that advises the commissioner and chief scientist. He previously served on two National Academy of Medicine (NAM) panels charged with reviewing the FDA, most recently the ethical and scientific issues in studying the safety of approved drugs. Dr. Psaty recently served as a member of NHLBI’s Advisory Council, and is a member of the NHLBI’s Board of External Experts. In 2013, he was elected to the NAM and designated a distinguished scientist by the American Heart Association.
For many years, Dr. Psaty maintained a small primary care practice in the Adult Medicine Clinic at Harborview Medical Center.
Jensen PN, Fretts AM, Hoofnagle AN, Sitlani CM, McKnight B, King IB, Siscovick DS, Psaty BM, Heckbert SR, Mozaffarian D, Sotoodehnia N, Lemaitre RN. Plasma ceramides and sphingomyelins in relation to atrial fibrillation risk: the Cardiovascular Health Study. J Am Heart Assoc. 2020;9(4):e012853. doi: 10.1161/JAHA.119.012853. Epub 2020 Feb 5. PubMed
Olson NC, Doyle MF, Sitlani CM, de Boer IH, Rich SS, Huber SA, Landay AL, Tracy RP, Psaty BM, Delaney JA. Associations of innate and adaptive immune cell subsets with incident type 2 diabetes risk: the MESA study. J Clin Endocrinol Metab. 2020 Jan 28. pii: 5716851. doi: 10.1210/clinem/dgaa036. [Epub ahead of print]. PubMed
Heckbert SR, Austin TR, Jensen PN, Chen LY, Post WS, Floyd JS, Soliman EZ, Kronmal RA, Psaty BM. Differences by race/ethnicity in the prevalence of clinically-detected and monitor-detected atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. Circ Arrhythm Electrophysiol. 2020 Jan 14. doi: 10.1161/CIRCEP.119.007698. [Epub ahead of print]. PubMed
Kalani R, Bartz TM, Suchy-Dicey A, Elkind MSV, Psaty BM, Leung LY, Rice K, Tirschwell D, Longstreth WT Jr. Cholesterol variability and cranial magnetic resonance imaging findings in older adults: the Cardiovascular Health Study. Stroke. 2020 Jan;51(1):69-74. doi: 10.1161/STROKEAHA.119.026698. Epub 2019 Dec 17. PubMed
Healthy Hearts Northwest is helping patients receive better care for cardiovascular conditions thanks to collaborators like Dr. L.J. Fagnan.
Dr. David Arterburn discusses reassuring news from his PCORnet study of the most widely used anti-obesity drug in the United States.
Researchers find a relationship between prescribed central nervous system-active medications and increased risk of falling among older people with dementia.